Sesen Bio Inc (SESN)

[averytheindian]

Eleven Biotherapeutics Incorporated (NASDAQ:EBIO) Sellers Covered 29.73% of Their Shorts

MARCH 19, 2016 BY STAFF WRITER IN STOCK NEWS · 0 COMMENT


The stock of Eleven Biotherapeutics Incorporated (NASDAQ:EBIO) registered a decrease of 29.73% in short interest. EBIO’s total short interest was 286,900 shares in March as published by FINRA. Its down 29.73% from 408,300 shares, reported previously. With 555,100 shares average volume, it will take short sellers 1 days to cover their EBIO’s short positions. The short interest to Eleven Biotherapeutics Incorporated’s float is 4.45%. The stock 0.03% or $0 on March 18, hitting $0.392. It is down 92.16% since August 13, 2015 and is downtrending. It has underperformed by 89.98% the S&P500.

Eleven Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $7.80 million. The Firm through AMP-Rx, a protein engineering platform, is engaged in the discovery and development of protein therapeutics to treat diseases of the eye. It currently has negative earnings. The Firm designs, engineers and generates a pipeline of protein therapeutic candidates that target cytokines, which are central to diseases of the eye.

The institutional sentiment decreased to 0.64 in 2015 Q3. Its down 0.29, from 0.93 in 2015Q2. The ratio worsened, as 16 funds sold all Eleven Biotherapeutics Inc shares owned while 6 reduced positions. 6 funds bought stakes while 8 increased positions. They now own 18.60 million shares or 31.23% more from 14.17 million shares in 2015Q2.

Flagship Ventures 2007 General Partner Llc holds 2.89% of its portfolio in Eleven Biotherapeutics Inc for 1.91 million shares. Third Rock Ventures Llc owns 4.84 million shares or 1.09% of their US portfolio. Moreover, Rotella Capital Management Inc. has 0.15% invested in the company for 190,947 shares. The California-based Redmile Group Llc has invested 0.04% in the stock. Sabby Management Llc, a New Jersey-based fund reported 171,541 shares.

Out of 2 analysts covering Eleven Biotherapeutics (NASDAQ:EBIO), 0 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means NaN are positive. Eleven Biotherapeutics was the topic in 4 analyst reports since August 15, 2015 according to StockzIntelligence Inc.